Guardian Wealth Advisors LLC Purchases 167 Shares of Johnson & Johnson (NYSE:JNJ)

Guardian Wealth Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,899 shares of the company’s stock after purchasing an additional 167 shares during the quarter. Johnson & Johnson accounts for 0.5% of Guardian Wealth Advisors LLC’s portfolio, making the stock its 24th largest holding. Guardian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $853,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Strategic Financial Concepts LLC increased its position in shares of Johnson & Johnson by 14,102.0% during the 4th quarter. Strategic Financial Concepts LLC now owns 311,876 shares of the company’s stock worth $45,104,000 after purchasing an additional 309,680 shares in the last quarter. Iron Horse Wealth Management LLC grew its stake in Johnson & Johnson by 33.2% during the fourth quarter. Iron Horse Wealth Management LLC now owns 3,296 shares of the company’s stock worth $477,000 after buying an additional 822 shares during the last quarter. Consolidated Portfolio Review Corp raised its stake in shares of Johnson & Johnson by 347.8% in the fourth quarter. Consolidated Portfolio Review Corp now owns 16,552 shares of the company’s stock valued at $2,394,000 after acquiring an additional 12,856 shares during the last quarter. Eagle Ridge Investment Management boosted its holdings in shares of Johnson & Johnson by 1.7% in the 4th quarter. Eagle Ridge Investment Management now owns 38,773 shares of the company’s stock worth $5,607,000 after acquiring an additional 665 shares in the last quarter. Finally, Citrine Capital LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $1,429,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $153.10 on Monday. The business has a 50-day simple moving average of $147.42 and a 200 day simple moving average of $156.08. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $368.61 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the firm earned $2.29 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analysts Set New Price Targets

A number of equities analysts have commented on JNJ shares. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Bank of America lowered their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Raymond James reduced their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.